Yantai Zhenghai Biotechnology Valuation
Is 300653 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 300653 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 300653 (CN¥21.51) is trading above our estimate of fair value (CN¥19.21)
Significantly Below Fair Value: 300653 is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 300653?
Key metric: As 300653 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is 300653's PE Ratio? | |
|---|---|
| PE Ratio | 22.9x |
| Earnings | CN¥167.68m |
| Market Cap | CN¥3.84b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 8.4x |
| Enterprise Value/EBITDA | 17.4x |
| PEG Ratio | 1.5x |
Price to Earnings Ratio vs Peers
How does 300653's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 71.9x | ||
603739 Qingdao Vland Biotech | 51x | 20.4% | CN¥3.4b |
300439 Medicalsystem Biotechnology | 17.6x | n/a | CN¥4.4b |
603387 Getein Biotech | 18.2x | n/a | CN¥4.6b |
300238 Guanhao BiotechLtd | 200.7x | n/a | CN¥3.5b |
300653 Yantai Zhenghai Biotechnology | 22.9x | 15.0% | CN¥3.8b |
Price-To-Earnings vs Peers: 300653 is good value based on its Price-To-Earnings Ratio (22.9x) compared to the peer average (71.9x).
Price to Earnings Ratio vs Industry
How does 300653's PE Ratio compare vs other companies in the CN Biotechs Industry?
| 0 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|
| 0 Companies | Estimated Growth | Market Cap |
|---|
Price-To-Earnings vs Industry: 300653 is good value based on its Price-To-Earnings Ratio (22.9x) compared to the CN Biotechs industry average (36x).
Price to Earnings Ratio vs Fair Ratio
What is 300653's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 22.9x |
| Fair PE Ratio | 21.8x |
Price-To-Earnings vs Fair Ratio: 300653 is expensive based on its Price-To-Earnings Ratio (22.9x) compared to the estimated Fair Price-To-Earnings Ratio (21.8x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | CN¥21.51 | CN¥29.25 +36.0% | 4.3% | CN¥30.50 | CN¥28.00 | n/a | 2 |
| Nov ’25 | CN¥23.48 | CN¥29.25 +24.6% | 4.3% | CN¥30.50 | CN¥28.00 | n/a | 2 |
| Oct ’25 | CN¥23.81 | CN¥30.12 +26.5% | 7.0% | CN¥32.23 | CN¥28.00 | n/a | 2 |
| Sep ’25 | CN¥19.41 | CN¥30.12 +55.2% | 7.0% | CN¥32.23 | CN¥28.00 | n/a | 2 |
| Aug ’25 | CN¥21.44 | CN¥32.58 +51.9% | 14.0% | CN¥37.15 | CN¥28.00 | n/a | 2 |
| Jul ’25 | CN¥20.35 | CN¥32.58 +60.1% | 14.0% | CN¥37.15 | CN¥28.00 | n/a | 2 |
| Jun ’25 | CN¥23.46 | CN¥32.58 +38.9% | 14.0% | CN¥37.15 | CN¥28.00 | n/a | 2 |
| May ’25 | CN¥23.61 | CN¥32.58 +38.0% | 14.0% | CN¥37.15 | CN¥28.00 | n/a | 2 |
| Apr ’25 | CN¥24.06 | CN¥34.84 +44.8% | 0.5% | CN¥35.00 | CN¥34.67 | n/a | 2 |
| Mar ’25 | CN¥23.74 | CN¥35.01 +47.5% | 0.01% | CN¥35.01 | CN¥35.00 | n/a | 2 |
| Feb ’25 | CN¥21.07 | CN¥35.01 +66.1% | 0.01% | CN¥35.01 | CN¥35.00 | n/a | 2 |
| Jan ’25 | CN¥29.02 | CN¥35.01 +20.6% | 0.01% | CN¥35.01 | CN¥35.00 | n/a | 2 |
| Dec ’24 | CN¥31.26 | CN¥35.01 +12.0% | 0.01% | CN¥35.01 | CN¥35.00 | n/a | 2 |
| Nov ’24 | CN¥30.72 | CN¥35.01 +13.9% | 0.01% | CN¥35.01 | CN¥35.00 | CN¥23.48 | 2 |
| Oct ’24 | CN¥31.98 | CN¥44.86 +40.3% | 6.6% | CN¥47.80 | CN¥41.91 | CN¥23.81 | 2 |
| Sep ’24 | CN¥30.59 | CN¥44.86 +46.6% | 6.6% | CN¥47.80 | CN¥41.91 | CN¥19.41 | 2 |
| May ’24 | CN¥46.05 | CN¥58.00 +26.0% | 5.2% | CN¥61.00 | CN¥55.00 | CN¥23.61 | 2 |
| Apr ’24 | CN¥44.93 | CN¥57.80 +28.6% | 5.5% | CN¥61.00 | CN¥54.60 | CN¥24.06 | 2 |
| Mar ’24 | CN¥45.62 | CN¥57.80 +26.7% | 5.5% | CN¥61.00 | CN¥54.60 | CN¥23.74 | 2 |
| Feb ’24 | CN¥47.79 | CN¥57.80 +20.9% | 5.5% | CN¥61.00 | CN¥54.60 | CN¥21.07 | 2 |
| Jan ’24 | CN¥43.00 | CN¥57.80 +34.4% | 5.5% | CN¥61.00 | CN¥54.60 | CN¥29.02 | 2 |
| Dec ’23 | CN¥42.13 | CN¥57.80 +37.2% | 5.5% | CN¥61.00 | CN¥54.60 | CN¥31.26 | 2 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.
Discover undervalued companies
Sichuan Kelun Pharmaceutical
CN¥49.3b
Researches, develops, manufactures, distributes, and sells pharmaceutical products in China.
2422
CN¥31.05
7D
3.7%
1Y
7.9%
Hunan Jiudian Pharmaceutical
CN¥11.8b
Researches, develops, produces, and sells pharmaceutical products in China and internationally.
300705
CN¥23.80
7D
-1.8%
1Y
12.8%
Jiangsu Kanion PharmaceuticalLtd
CN¥8.1b
Researches and develops, produces, and sells Chinese medicines.
600557
CN¥14.20
7D
-3.1%
1Y
-24.5%